statnews.com·Apr 28, 2026
Boehringer's obesity drug demonstrated a weight loss of 16.6%, but further data is required to confirm its efficacy. The article also highlights Eli Lilly's new partnership with Profluent for gene editing development and discusses recent challenges faced by other biotech companies.
Eli Lilly's recent partnership with AI-focused biotech Profluent to develop advanced gene editors highlights a significant investment signal in the field of AI-driven drug discovery and precision medicine. This move indicates a strategic focus on leveraging AI to enhance gene-editing capabilities, potentially transforming therapeutic approaches and offering new opportunities for innovation in the biotech sector.